Led · Series A · Nov 2022

Micron Biomedical develops a dissolvable microarray-based, needle-free platform for administration of drugs and vaccines. Its proprietary technology is designed to enable injection-free, painless and simple or self-administration, and to reduce or eliminate cold-chain requirements. The platform aims to enhance safety and efficacy while improving patient compliance. The company is led by CEO Steve Damon and is based in Atlanta, GA. Micron intends to use newly raised funds to expand operations and its R&D sector. Financially, the company extended its Series A to over $33M following the latest financing. Micron Biomedical is a clinical-stage life science company developing dissolvable microarray-based products for injection-free, painless administration of drugs and vaccines. Its core product is a microarray technology that reduces or eliminates cold chain requirements and enables community health workers to vaccinate quickly by applying a patch and pressing a button to confirm administration. Micron reported successful phase I/II clinical data in the Gambia across adults, toddlers, and infants as young as nine months using a leading commercial measles-rubella vaccine delivered via its microarray. The company plans to build a commercial-scale manufacturing facility—funded by a $23.6M Gates Foundation grant—to mass-produce needle-free vaccines and support larger clinical trials and regulatory approvals. Micron’s technology aims to expand vaccine access in low- and middle-income countries, improve patient acceptance in higher-income markets, and strengthen US national, veteran, and military health. Micron partners with the Bill & Melinda Gates Foundation, the CDC, PATH, and the Georgia Research Alliance and previously received a Gates grant in 2017 that enabled its first pediatric clinical trial. Micron Biomedical is an Atlanta-based life sciences company advancing dissolvable microarray-based drug and vaccine administration technology. Its patented microarray technology enables drugs and vaccines that today require cold storage and injection to be self-administered or caregiver-administered within minutes without refrigeration or a skilled health professional. The company aims to bring its dissolvable microarray products to markets globally. Micron has partnered with or received funding from private and public pharmaceutical and biotech companies as well as the Bill & Melinda Gates Foundation, the CDC, UNICEF, PATH and the Georgia Research Alliance. The company is led by CEO Steven Damon. The Series A extension will further support commercialization and global market efforts. Micron Biomedical is a clinical-stage life sciences company advancing its Micro Array Patch (MAP) technology to enable self-administration and less-skilled caregiver administration of drugs and vaccines without needles. Led by CEO Steven Damon and based in Atlanta, GA, the company’s pipeline includes vaccine and drug products partnered with pharmaceutical companies, foundations, and government agencies. Micron has demonstrated clinical efficacy for its MAP technology and since inception has supported R&D with more than $40 million in non-dilutive financing. The company intends to use the new funds to develop commercial manufacturing capacity, which is currently underway. Micron has received support and funding from foundations and public health organizations that have partnered on development and trials.